Status:

UNKNOWN

A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC

Lead Sponsor:

Southwest Hospital, China

Conditions:

Hepatocellular Carcinoma Recurrent

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

To observe and compare the short-term and long-term oncological outcome of laparoscopic hepatectomy and radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma .

Detailed Description

Background \& Aims: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death in the world. The 5-year recurrent rate of HCC after first curative resection is 77%\~100%. Laparo...

Eligibility Criteria

Inclusion

  • Any gender,18 to 70 years old;
  • Preoperative diagnosis of recurrent HCC clear,liver resection was done previously;
  • No active hepatitis and decompensated cirrhosis;
  • Patient with previous liver resection, maximum diameter ≤5cm single recurrent nodules or 3 nodules in diameter and no more than 3cm,did not infringe the portal vein,hepatic vein and inferior vena cava invasion,lymph node or extrahepatic turn;
  • No tumor rupture or bleeding;
  • Child-Pugh class A or B grade,ICG-R15 \<20%;
  • No coagulation disorders,platelet count \> 50 × 109 / L and prolonged prothrombin time \< 5 seconds;
  • After diagnosis of recurrent HCC,not be including related surgery,radiofrequency ablation (RFA),TACE treatment,no certainty anticancer chemotherapy treatment;supreme absolute contraindications abdominal surgery;
  • Recurrent nodules are not close to intestines,stomach,cholecyst or diaphragm muscle, not close to the first porta hepatis,main vessel and biliary ducts;
  • Patients generally available,heart and lung function can tolerate surgery, abdominal surgery supreme absolute contraindications;
  • Voluntarily participate in the study, voluntarily accept any therapy of two,informed consent.

Exclusion

  • Opposite of the above inclusion criteria;
  • Severe upper abdominal adhesions;
  • Postoperative pathological examination of the bile duct cell or mixed cell carcinoma and pathologically confirmed positive margin;
  • Foreign,Hong Kong,Macao,Taiwan and other regions,estimated postoperative difficult to track,followed up;
  • Nodules proved to be not recurrent HCC during intraoperative exploration, such as:liver metastases of colorectal cancer.

Key Trial Info

Start Date :

September 1 2016

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2021

Estimated Enrollment :

180 Patients enrolled

Trial Details

Trial ID

NCT03313648

Start Date

September 1 2016

End Date

September 1 2021

Last Update

October 18 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Southwest Hospital

Chongqing, Chongqing Municipality, China, 400038

A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC | DecenTrialz